Clinical Trials

Numerous clinical trials investigate therapeutic and diagnostic protocols across diverse indications, encompassing oncological conditions such as non-small cell lung cancer, colorectal cancer, and medulloblastoma, as well as non-oncology disorders like Parkinson disease, autoimmune diseases, and shoulder osteoarthritis. Spanning Phase 1 through Phase 4 and non-applicable study designs, these trials are supported by academic institutions and industry sponsors, such as the Mayo Clinic and AstraZeneca. Recruitment statuses range from actively recruiting and not yet recruiting to active, not recruiting and completed.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07311213 NOT_YET_RECRUITING
Autism Disorder; ASD
Institut National de la Santé Et de la Recherche Médicale, France
 2026-08-01
NCT06193759 RECRUITING
Medulloblastoma, Childhood; Atypical Teratoid/Rhabdoid Tumor of CNS; Embryonal Tumor With Multilayered Rosettes; Pineoblastoma; Embryonal Brain Tumor Not Otherwise Specified; Ependymoma
Children's National Research Institute
 2024-09-20 PHASE1
NCT03838926 RECRUITING
Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
 2018-09-27 PHASE1
NCT07303413 NOT_YET_RECRUITING
Autism Spectrum Disorder
Institut Pasteur
 2026-01
NCT05395819 ACTIVE_NOT_RECRUITING
Shoulder Osteoarthritis
University of Alberta
 2022-05-30
NCT04864158 RECRUITING
Rotator Cuff Arthropathy
University of Aarhus
 2021-05-28
NCT03839758 RECRUITING
Shoulder Arthritis
Université de Montréal
 2019-10-08
NCT05473429 RECRUITING
Intellectual Disability
National Institutes of Health Clinical Center (CC)
 2026-03-27
NCT07065773 ACTIVE_NOT_RECRUITING
Onychomycosis of Toenail
Vanda Pharmaceuticals
 2025-05-05 PHASE2
NCT05786898 RECRUITING
Autism Spectrum Disorder
Centre Hospitalier St Anne
 2023-01-24
NCT04845074 COMPLETED
Glenohumeral Osteoarthritis
University of Aarhus
 2021-06-02
NCT05666674 UNKNOWN
Tremor
NeuroStorm, Inc
 2022-08-01
NCT05524519 COMPLETED
Major Depressive Disorder
The Third Affiliated hospital of Zhejiang Chinese Medical University
 2022-11-01
NCT05355363 Recruiting
Colorectal Cancer|Colon Adenoma
Centre hospitalier de l''Université de Montréal (CHUM)
 2023-02-27 Not Applicable
NCT06109415 COMPLETED
Postoperative Pain; Total Shoulder Arthroplasty; Multimodal Analgesia
Heron Therapeutics
 2021-10-20 PHASE4
NCT05414890 Recruiting
NMO Spectrum Disorder|NMDA-R Encephalitis|Diagnostic Self Evaluation|Immune System Diseases|Nervous System Diseases|Autoimmune Diseases of the Nervous System|Autoimmune Diseases
Beijing Tiantan Hospital|Tianjin Medical University General Hospital
 2022-06-30 --
NCT05271955 Not yet recruiting
Autism Spectrum Disorder
Assistance Publique - Hôpitaux de Paris|University Hospital Montpellier
 2022-06-15 Not Applicable
NCT03735173 COMPLETED
Arthropathy Shoulder; Shoulder Pain; Shoulder Osteoarthritis; Shoulder Arthritis; Shoulder Arthropathy Associated With Other Conditions; Necrosis of Bone; Arthritis; Inflammatory Arthritis
Mayo Clinic
 2018-12-01
NCT03913091 COMPLETED
Shoulder Pain
NYU Langone Health
 2019-03-01 PHASE4
NCT02959905 COMPLETED
Solid Cancer
BGI, China
 2016-12-22 PHASE1
NCT04606771 Active not recruiting
Non-Small Cell Lung Cancer
AstraZeneca
 2020-09-28 Phase 2
NCT03877510 Completed
Parkinson Disease
Impax Laboratories LLC
 2019-04-03 Phase 3
NCT03133819 UNKNOWN
Diabetes; Neuropathy, Polyneuropathy (Manifestation)
Chang Gung Memorial Hospital
 2016-11
NCT02486965 COMPLETED
Fibromyalgia
University Hospital, Brest
 2015-10-07
NCT02695758 COMPLETED
Osteoarthritis: Shoulder
Rothman Institute Orthopaedics
 2014-12
NCT01905241 COMPLETED
Anatomic Total Shoulder Arthroplasty
The Cleveland Clinic
 2013-07
NCT01801241 COMPLETED
Anatomic Total Shoulder Arthroplasty
The Cleveland Clinic
 2013-01
NCT01575106 COMPLETED
Pain
Massachusetts General Hospital
 2012-06
NCT02762903 COMPLETED
Osteoarthritis
Columbia University
 2009-08
NCT00914173 COMPLETED
Pain
Medasense Biometrics Ltd
 2008-11

(data from https://clinicaltrials.gov, updated on 2026-06-05)

Check the Trichostatin A (TSA) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Trichostatin A acts as a potent histone deacetylase inhibitor that binds the catalytic site of histone deacetylases, blocking core histone deacetylation and inducing hyperacetylation of histone H4. This alteration in chromatin architecture suppresses cellular proliferation and promotes cytostatic differentiation, thereby inhibiting tumor cell growth in clinical trial indications such as non-small cell lung cancer and colorectal malignancies.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.